Xtl Biopharmaceuticals XTLB
NASDAQ XTLB
$2.21 -0.02 (-0.91%)
As of: Sep 29, 2026 · 3:40 PM EDT

Xtl Biopharmaceuticals (XTLB) EBITDA Margin (2013 - 2014)

Updated

Xtl Biopharmaceuticals (XTLB) recorded EBITDA Margin of -127.72% in the year ended Dec 31, 2024.

Analysis

Xtl Biopharmaceuticals (XTLB) EBITDA Margin (2013 - 2014) Analysis & Trends

Starting with the year ended Dec 31, 2010, Xtl Biopharmaceuticals' EBITDA Margin history includes 6 years.

  • Annual EBITDA Margin has a four-year change of +8481.37 percentage points (years ended Dec 2020 to Dec 2024).
  • The figure for the year ended Dec 31, 2024 is the highest annual EBITDA Margin since the year ended Dec 31, 2013.
  • Per Business Quant data, XTLB's EBITDA Margin was -8609.09% in the year ended Dec 31, 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Xtl Biopharmaceuticals 2.11 Bn 2.11 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2014 -124.04%
Jun 30, 2014 -103.16%
Mar 31, 2014 -97.79%
Dec 31, 2013 115.47%
Sep 30, 2013 191.54%
Jun 30, 2013 -179.88%
Mar 31, 2013 -125.56%
API Access

Xtl Biopharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=XTLB&period=max&api_key=YOUR_API_KEY